Tag: odanacatib

1. The cathepsin K inhibitor odanacatib reduced the risk of fracture but was associated with significantly increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis compared to placebo. Evidence Rating Level: 1 (Excellent) Odanacatib, a cathepsin K inhibitor, reduces bone resorption without compromising bone formation, with further findings suggesting...
Odanacatib for the Treatment of Postmenopausal Osteoporosis: Results of the LOFT Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial and LOFT Extension Study 1. The cathepsin K inhibitor odanacatib reduced the risk of fracture but was associated with significantly increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis compared to...